Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Human respiratory syncytial virus (RSV) causes acute respiratory illness, attributing to deaths among young children and older adults worldwide. RSV neutralization assay is an important tool to measure RSV neutralization antibody that can prevent infection and severe complication of RSV. Conventional RSV neutralization assays have some limitations of speed and cost, especially for expensive kits, reagents or instruments required for detection. To solve this problem, this paper describes an improved simple and economical RSV neutralization assay protocol using recombinant RSV (rRSV) expressing reporter fluorescent protein to measure RSV growth as reporter activity with plate reader. The condition of 3 days culture demonstrated sufficient fluorescent activity even when small amounts of rRSV were used to inoculate Hep-2 cells. In addition, white 96-well cell culture plate showed better stable reporter activities than black plate. Furthermore, RSV neutralization assay protocol using rRSV-reporter fluorescent protein demonstrated similar signal detection capacity for RSV antibody titer detection compared to other protocols, such as rRSV-Luciferase and ELISA assay. The new RSV neutralization assay protocol can be applied to RSV antibody titration of numerous samples necessary for RSV surveillance or antiviral testing.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12196034 | PMC |
| http://dx.doi.org/10.3390/mps8030060 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: a systematic review of Arexvy, Abrysvo, and mResvia.
Front Immunol
September 2025
Department of Microbiology and Parasitology and Parasitology, College of Medicine, Umm Al-Qura University, Makkah, Makkah, Saudi Arabia.
Background: Respiratory Syncytial Virus (RSV) poses a major health threat to older adults, pregnant women, and high-risk populations. We systematically evaluated the efficacy, immunogenicity, and safety of three FDA-approved RSV vaccines: Arexvy, Abrysvo, and mResvia.
Methods: Following PRISMA 2020 guidelines, we searched PubMed, ClinicalTrials.
Rational design of respiratory syncytial virus dimeric F-subunit vaccines in protein and mRNA forms.
EBioMedicine
August 2025
Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China; Beijing Life Science Academy, Beijing, 102209, China; University of Chinese Academy of Sciences, Beijing, 101408, China. Electronic address:
Background: Respiratory syncytial virus (RSV) poses a significant public health threat, particularly to children and the elderly. Two protein-based vaccines and one mRNA vaccine have been approved, all targeting the prefusion conformation of the fusion (F) trimer. However, it has been reported that the epitope activity of the F protein gradually declines during storage, resulting in a reduction of the vaccines' immunogenicity.
View Article and Find Full Text PDFImmunogenicity, Safety, and Protective Efficacy of Mucosal Vaccines Against Respiratory Infectious Diseases: A Systematic Review and Meta-Analysis.
Vaccines (Basel)
July 2025
Nanshan School, Guangzhou Medical University, Guangzhou 510180, China.
Mucosal vaccines, delivered intranasally or via inhalation, are being studied for respiratory infectious diseases like COVID-19 and influenza. These vaccines aim to provide non-invasive administration and strong immune responses at infection sites, making them a promising area of research. This systematic review and meta-analysis assessed their immunogenicity, safety, and protective efficacy.
View Article and Find Full Text PDFSecretory Expression and Purification of Respiratory Syncytial Virus G and F Ectodomain in Human Cells.
Methods Mol Biol
August 2025
Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA, USA.
Respiratory syncytial virus (RSV) is one of the leading causes of respiratory viral infections in infants, immunocompromised individuals, and the elderly. The important role RSV F and G proteins play in disease progression and their ability to induce neutralizing antibodies make them desirable targets for vaccine production. Access to these expressed and purified proteins is also important to RSV research and diagnostics.
View Article and Find Full Text PDFFactors associated with respiratory syncytial virus-neutralizing antibody titers in adults.
J Infect Chemother
August 2025
Women's Internal Medicine, Women's Health Center, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, Tokyo, 157-8535, Japan. Electronic address:
Background: Respiratory syncytial virus (RSV) is associated with high morbidity in children. Despite recent advances in vaccine development for adults and maternal vaccination strategies to protect newborns, data on RSV seroprevalence and neutralizing antibody titers in adults remain limited. This study aimed to measure RSV-neutralizing antibody titers in adults and explore associated background characteristics.
View Article and Find Full Text PDF